Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
Should You Buy This Stock After It Skyrocketed by 33%?
Doximity recently reported strong financial results. The company has solid growth opportunities.
Reconsidering Doximity Shares: Should Investors Bet On A Sustained Revenue Growth Inflection
Doximity's guidance in no way reflects the positive tea leaves management discussed during the conference call. Doximity reported better than expected Q1 results with revenues of $127 million and adjusted EBITDA of $66 million, leading to a 39% increase in share price. The company minimally increased its adjusted EBITDA forecast for FY '25, but potential for sustainable growth rates is not reflected in consensus estimates.
Doximity: The 'Facebook for Doctors' Surges After Earnings Beat
Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research.
Doximity: Q1 Earnings Mark A Possible Turnaround For The Company (Rating Upgrade)
Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.
Why Doximity Stock Was Soaring Today
Doximity beat estimates on the top and bottom lines. The company continues to report strong margins.
Why Is Doximity (DOCS) Stock Up 30% Today?
Doximity (NYSE: DOCS ) stock is rising higher on Friday following the release of the medical cloud-based digital platform company's earnings report for its fiscal first quarter of 2025. That earnings report starts off strong with adjusted EPS of 28 cents per share.
Doximity Stock Jumps 31%. Here's Why.
The medical platform's quarterly result beat expectations on both top and bottom lines, and is also leveraging AI to appeal to customers.
Doximity, Inc. (DOCS) Q1 2025 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:50 PM ET Doximity, Inc. (NYSE:DOCS ) Q1 2025 Earnings Conference Call August 08, 2024, 17:00 PM ET Company Participants Jeff Tangney - Co-founder and CEO Nate Gross - Co-founder and CSO Anna Bryson - CFO Perry Gold - VP of IR Conference Call Participants Brian Peterson - Raymond James Scott Berg - Needham & Company Stephanie Davis - Barclays Jared Hass - William Blair John Pinney - Canaccord Genuity Allen Lutz - Bank of America Elizabeth Anderson - Evercore ISI Jessica Tassan - Piper Sandler Michael Cherny - Leerink Partners Craig Hettenbach - Morgan Stanley Jenny Cao - Truist Securities Stan Berenshteyn - Wells Fargo Securities Jenny Shen - BTIG Operator Good day, everyone, and welcome to the Doximity Fiscal First Quarter 2025 Earnings Call. At this time, I would like to hand things over to Vice President of Investor Relations, Perry Gold.
Doximity (DOCS) Q1 Earnings and Revenues Surpass Estimates
Doximity (DOCS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
Gear Up for Doximity (DOCS) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Doximity (DOCS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
